Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,289,900 papers from all fields of science
Search
Sign In
Create Free Account
alahopcin
Known as:
2-((alanyl)amino)-4-formyl-3-(hydroxyaminocarbonyl)butyric acid
, L-Norvaline, N-L-alanyl-3-((hydroxyamino)carbonyl)-5-oxo-, threo-
, nourseimycin
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Peptides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1985
1985
Structure of alahopcin (nourseimycin), a new dipeptide antibiotic.
S. Horii
,
H. Fukase
,
+5 authors
A. Isogai
Journal of antibiotics (Tokyo. )
1985
Corpus ID: 20823283
The structure of alahopcin (nourseimycin) (1), a new dipeptide antibiotic isolated from Streptomyces, has been established to be…
Expand
1985
1985
Alahopcin, a new dipeptide antibiotic produced by Streptomyces albulus subsp. ochragerus subsp. nov.
E. Higashide
,
S. Horii
,
+4 authors
M. Yoneda
Journal of antibiotics (Tokyo. )
1985
Corpus ID: 21780728
An actinomycete strain No. B-52653 was found to produce an antibiotic selectively active against the in vitro antibiotic…
Expand
1985
1985
Isolation of dealanylalahopcin, a new amino acid, and its biological activity.
E. Higashide
,
T. Kanamaru
,
H. Fukase
,
S. Horii
Journal of antibiotics (Tokyo. )
1985
Corpus ID: 43792928
A new amino acid, dealanylalahopcin, was isolated from a culture filtrate of Streptomyces albulus subsp. ochragerus; it was also…
Expand
1983
1983
Isolation and Biological Activities of Nourseimycin, a New Antimetabolite of l-Proline
H. Nishida
,
Michito Tagawa
,
A. Hirota
,
A. Isogai
,
H. Sakai
1983
Corpus ID: 4985947
A new antimetabolite, nourseimycin, an antagonist of l-proline, was isolated from the fermentation broth of a strain of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE